NOVO B NOVO NORDISK A/S

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonChristina Law 
2 Reason for the notification 
a)Position/statusMember of the Board of Directors 
b)Initial notification/AmendmentInitial notification 
3 Details of the issuer 
a)NameNovo Nordisk A/S 
b)LEI549300DAQ1CVT6CXN342 
4 Details of the transaction(s) 
a)Description of the financial instrument,

type of instrument,
ADRs



 
 Identification codeNVO 
b)Nature of the transactionPurchase of ADRs 
c)







Price(s) and volume(s)







 Price(s)Volume(s)  
 DKK 349.06952 ADRs  
 DKK 349.04598 ADRs  
   DKK 349.03800 ADRs  
d)Aggregated information
  • Aggregated volume
  • Price




2,350 ADRs

DKK 820,252.49
 
e)Date of the transaction2025-08-18 
f)Place of the transactionNew York Stock Exchange 



Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 78,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit  , , , and .



Contacts for further information

Media: 
Ambre James-Brown







Liz Skrbkova (US)







Investors: 
Jacob Martin Wiborg Rode







Sina Meyer







Max Ung







Christoffer Sho Togo Tullin







Alex Bruce







Frederik Taylor Pitter









Attachment



EN
19/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NOVO NORDISK A/S

 PRESS RELEASE

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 9 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repurch...

 PRESS RELEASE

Election of employee representatives to the Board of Directors of Novo...

Election of employee representatives to the Board of Directors of Novo Nordisk A/S Bagsværd, Denmark, 2 March 2026 – The employees in Novo Nordisk A/S have completed the election of employee representatives to the Board of Directors of Novo Nordisk A/S. The following employee representatives were elected for the next four years: Semsi Kilic Madsen (new)Mette Bøjer Jensen (re-elected)Elisabeth Dahl Christensen (re-elected)Désirée Jantzen Asgreen (new) The following were elected as substitutes for the employee-elected board members: Trine Hartvig KristiansenTamara SchmidtTanja VillumsenHa...

 PRESS RELEASE

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 2 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will repurch...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch